<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758964</url>
  </required_header>
  <id_info>
    <org_study_id>EARTH - TAVR 01</org_study_id>
    <nct_id>NCT02758964</nct_id>
  </id_info>
  <brief_title>Evaluation of Cerebral Thrombembolism After TAVR</brief_title>
  <acronym>EARTH - TAVR</acronym>
  <official_title>Evaluation of Cerebral Thrombembolism After TAVR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      EARTH-TAVR is a diagnostic multicenter study to evaluate the occurrence and extent of
      cerebral embolization (total new lesion volume) in patients before TAVR versus 3 months after
      TAVR.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calcific aortic valve stenosis is the most common cause of aortic stenosis (AS) among adults
      in Europe and in the United States. The prevalence of moderate or severe AS was found to be
      age-dependent rising from 0.02% in patients aged 18-44 years to 2.8% in patients aged ≥ 75
      years. Among patients at prohibitive surgical risk, TAVR has become the treatment of
      choice.The safety and efficacy of TAVR compared with medical management and SAVR has been
      demonstrated in clinical trials.The composite of the rate of all-cause death or stroke was
      27% and 37% in TAVR patients after 1 and 2 years, respectively.Even though parts of the
      strokes occur during the peri-procedural period, the patients remain at risk of stroke
      throughout the first months after the procedure.

      EARTH-TAVR is a diagnostic multicenter study performing in association with the GALILEO trial
      (NCT02556203), which is investigating cerebral embolization with MRI and neurocognitive
      testing in patients undergoing TAVR, who are treated with anticoagulation (Rivaroxaban/ASS)
      or DAPT (Clopidogrel/ASS). GALILEO is a global multicenter, open-label, randomized,
      event-driven, active-controlled study comparing a rivaroxaban-based antithrombotic strategy
      to an antiplatelet-based strategy after transcatheter aortic valve replacement (TAVR) to
      optimize clinical outcomes.

      Investigators aim to investigate peri-interventional and delayed cerebral embolization in the
      early period (3 months) after TAVR and to analyze associations between neurocognitive
      parameters and cerebral embolization patterns in patients on different antithrombotic
      treatment regimes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total volume of new cerebral lesions on MRI, 3 months after TAVR versus Baseline</measure>
    <time_frame>3 months after TAVR versus baseline</time_frame>
    <description>Occurrence and extent of cerebral embolization in patients after TAVR measured by total volume of new ischemic cerebral lesions on DWI and FLAIR MRI.
Total new lesion volume is defined as the sum volume of all new cerebral ischemic lesions on the 3 months post-procedural MRI relative to the pre-TAVR cerebral MRI scan (on diffusion weighted and FLAIR MRI images)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New lesion volume of cerebral embolization in patients treated with ASS and rivaroxaban 10mg OD versus an antiplatelet -based strategy with ASS and clopidogrel.</measure>
    <time_frame>3 months post TAVR versus baseline</time_frame>
    <description>Total new lesion volume is defined as the sum volume of all new cerebral ischemic lesions on the 3 months post-procedural MRI relative to the pre-TAVR cerebral MRI scan (on diffusion weighted and FLAIR MRI images).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>extent and location of new cerebral lesions early AFTER TAVR and after 3 months</measure>
    <time_frame>MRI after TAVR (0-7 days after TAVR) compared to 3 months after TAVR</time_frame>
    <description>To evaluate cerebral embolisation, which is not procedure related, cerebral embolisation on MRI will be compared 3 months post TAVR versus the post-TAVR MRI scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of different neurocognitive tests (NIHSS-score, MOCA-score, MOT-score, PAL-score, RTI-score, SWM-score, AST-score, CAM-Score); change of sum scores before, after and 3 months after TAVR procedure.</measure>
    <time_frame>Before TAVR, post TAVR and after 3 months</time_frame>
    <description>To evaluate neurologic function with a battery of neurocognitive tests and to correlate these findings to cerebral MRI scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent and localization of clinically apparent non-cerebral emboli after TAVR</measure>
    <time_frame>baseline, post TAVR and after 3 months</time_frame>
    <description>To describe extent and localization of non-cerebral embolisation (e.g. pulmonary embolism, limb ischaemia...)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of possible changes in quality of life after TAVI with EQ-5D questionnaire sum score.</measure>
    <time_frame>Baseline versus 3 months following TAVR</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <condition>Intracranial Embolism</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI, neurocognitive Testing</intervention_name>
    <description>A cerebral MRI and neurocognitive testing will be performed before TAVR, before hospital discharge and after 3 months</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 18 years or older wirth aortic valve stenosis receiving TAVR-Intervention.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman of 18 years of age or older

          -  Via iliofemoral or subclavian access

          -  Provide written IC

        Exclusion Criteria:

          -  Atrial fibrillation (AF), current or previous, with an ongoing indication for oral
             anticoagulant Treatment

          -  Any other indication for continued treatment with any oral anticoagulant (OAC)

          -  Known bleeding diathesis (such as but not limited to active internal bleeding,
             clinically significant bleeding, platelet count ≤ 50,000/mm3 at screening, hemoglobin
             level &lt; 8.5 g/dL, active peptic ulcer or known gastrointestinal (GI) bleeding, history
             of intracranial hemorrhage or subdural hematoma)

          -  Any indication for dual-antiplatelet therapy (DAPT) for more than 3 months after
             randomization (such as coronary, carotid or peripheral stent implantation)

          -  Clinically overt stroke within the last 3 months

          -  Planned coronary or vascular intervention or major surgery

          -  Severe renal impairment (eGFR &lt; 30 mL/min/1.73 m2) or on dialysis, or post-TAVR
             unresolved acute kidney injury with renal dysfunction stage 2 or higher

          -  Moderate and severe hepatic impairment (Child-Pugh Class B or C) or any hepatic
             disease associated with coagulopathy

          -  Any contraindication for cerebral MRI, in particular:

          -  non-MRI-conditional pacemakers

          -  MRI conditional pacemakers &lt;4 weeks after implant

          -  any metal fragments in the eye

          -  aneurysm clip in the brain

          -  severe claustrophobia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf Landmesser, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité - Universitätsmedizin Berlin, Department of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthias Endres, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Charité - Universitätsmedizin Berlin, Department of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georg M Fröhlich, PD</last_name>
    <role>Study Chair</role>
    <affiliation>Charité - Universitätsmedizin Berlin, Department of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Volkmar Falk, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>German Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georg Fröhlich, PD Dr.</last_name>
    <phone>+49 (0) 30 450 513 702</phone>
    <email>georg.froehlich@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Steinbeck, Dr.</last_name>
    <email>lisa.steinbeck@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Verena Stangl, Prof. Dr. med.</last_name>
      <phone>004930450513072</phone>
      <email>verena.stangl@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Henryk Dreger, PD Dr. med.</last_name>
      <phone>004930450513072</phone>
      <email>henryk.dreger@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Verena Stangl, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henryk Dreger, PD Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Fröhlich, PD Dr. med.</last_name>
      <phone>004930450513728</phone>
      <email>georg.froehlich@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Steinbeck</last_name>
      <phone>004930450513728</phone>
      <email>lisa.steinbeck@charite.de</email>
    </contact_backup>
    <investigator>
      <last_name>Ulf Landmesser, Prof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georg Fröhlich, PD Dr. med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.cardialysis.com/galileo/</url>
    <description>GALILEO main study</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/NCT02556203?term=GALILEO&amp;rank=7</url>
    <description>GALILEO study</description>
  </link>
  <reference>
    <citation>Holmes DR Jr, Brennan JM, Rumsfeld JS, Dai D, O'Brien SM, Vemulapalli S, Edwards FH, Carroll J, Shahian D, Grover F, Tuzcu EM, Peterson ED, Brindis RG, Mack MJ; STS/ACC TVT Registry. Clinical outcomes at 1 year following transcatheter aortic valve replacement. JAMA. 2015 Mar 10;313(10):1019-28. doi: 10.1001/jama.2015.1474.</citation>
    <PMID>25756438</PMID>
  </reference>
  <reference>
    <citation>Osnabrugge RL, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, LeReun CM, Bogers AJ, Piazza N, Kappetein AP. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol. 2013 Sep 10;62(11):1002-12. doi: 10.1016/j.jacc.2013.05.015. Epub 2013 May 30.</citation>
    <PMID>23727214</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Ulf Landmesser</investigator_full_name>
    <investigator_title>Prof. Dr. Ulf Landmesser</investigator_title>
  </responsible_party>
  <keyword>TAVR</keyword>
  <keyword>TAVI</keyword>
  <keyword>Transcatheter Aortic Valve Replacement</keyword>
  <keyword>Intracranial Embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Intracranial Embolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

